Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.59 |
| ▸ | PIM1 | P11309 | 3/20 | 0.59 |
| ▸ | PRKACA | P17612 | 3/20 | 0.59 |
| ▸ | CLK2 | P49760 | 3/20 | 0.59 |
| ▸ | GSK3B | P49841 | 3/20 | 0.59 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.59 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.59 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.59 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.59 |
| ▸ | CDK9 | P50750 | 3/20 | 0.59 |
| ▸ | KDR | P35968 | 2/20 | 0.59 |
| ▸ | PRKX | P51817 | 2/20 | 0.59 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.59 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.59 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.59 |
| ▸ | CDK8 | P49336 | 1/20 | 0.59 |
| ▸ | CDK7 | P50613 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1852708 | 0.92 | CDK9 (0.60) | CHEK1MAP4K4PIM1PRKACACLK2 | |
| SCHEMBL1851509 | 0.88 | CHEK1 (0.62) | CHEK1MAP4K4PIM1PRKACACLK2 | |
| SCHEMBL1852346 | 0.87 | CHEK1 (0.58) | CHEK1MAP4K4PIM1PRKACACLK2 | |
| SCHEMBL1853760 | 0.86 | CHEK1 (0.62) | CHEK1MAP4K4PIM1PRKACACLK2 | |
| SCHEMBL3604253 | 0.86 | CHEK1 (0.62) | CHEK1MAP4K4PIM1PRKACACLK2 | |
| SCHEMBL1850377 | 0.86 | CHEK1 (0.62) | CHEK1MAP4K4PIM1PRKACACLK2 | |
| SCHEMBL1849796 | 0.86 | CHEK1 (0.62) | CHEK1MAP4K4PIM1PRKACACLK2 | |
| SCHEMBL1849976 | 0.85 | CHEK1 (0.69) | CHEK1MAP4K4PIM1PRKACACLK2 | |
| SCHEMBL1850762 | 0.83 | CHEK1 (0.65) | CHEK1MAP4K4PIM1PRKACACLK2 | |
| SCHEMBL1848432 | 0.83 | CHEK1 (0.61) | CHEK1MAP4K4PIM1PRKACACLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323659-A1 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | Abbott Laboratories (US) | 2011-05-25 | — | — | EP | claimed |
| WO-2010017150-A1 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | WO | claimed |
| US-20100035919-A1 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| CN-102170883-A | Compounds useful as inhibitors of protein kinases | ABBOTT LAB | 2011-08-31 | — | — | CN | disclosed |
| EP-2323659-A1 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | Abbott Laboratories (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010017150-A1 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035919-A1 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035919-A1 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | ROCK1, ROCK2, RHOA | CHEK1 434/4885MAP4K4 105/4885PIM1 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.